Abstract
Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues
Highlights
Serious hypoglycemia is a major, potentially fatal adverse event caused by insulin secretagogues.[1]
Adjusted rate ratios (RRs) for serious hypoglycemia with concomitant calcium-channel blocker (CCB) use were reduced with glimepiride (0.79; 0.70-0.89), glipizide (0.86; 0.79-0.94), glyburide (0.81; 0.73-0.90), and metformin (0.91; 0.86-0.96)
Calcium-channel blockers used concomitantly with insulin secretagogues were associated with reduced rates of serious hypoglycemia compared with the use of insulin secretagogues without CCBs
Summary
Serious hypoglycemia is a major, potentially fatal adverse event caused by insulin secretagogues.[1]. Because insulin secretion by the pancreas is mediated by calcium influx in beta cells through calcium channels,[4] we conducted a population-based observational study on the hypothesis that concomitant use of CCBs may be associated with reduced rates of serious hypoglycemia in insulin secretagogue users
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
